|
Article Excerpt
M2 PRESSWIRE-31 July 2007-PennyPerformers.com: PennyPerformers.com: Penny Stocks that OutPerform the Competition ---Tuesday, July 31st --- SOBM, CEMI, ONEV, DIAAF, NIHK, GOJO(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:31072007
PennyPerformers.coms "Penny Stocks that Perform" for today are: Sinobiomed Inc.(OTCBB: SOBM), Chembio Diagnostics, Inc. (OTCBB: CEMI), One Voice Technologies, Inc. (OTCBB:ONEV), Diamant Art Corporation (OTCBB: DIAAF), Nighthawk Systems, Inc. (OTCBB: NIHK), GraphOn Corporation (OTCBB:GOJO)
Sign-up for our FREE Stock Alerts at http://www.PennyPerformers.com and click here for our full Disclaimer at http://www.PennyPerformers.com/disclaimer.htm
Sinobiomed Inc. (OTCBB: SOBM) http://www.PennyPerformers.com Sinobiomed Inc. is pleased to announce today that Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing"), the Company's 82% owned subsidiary, has received the patent grant notice from the State Intellectual Property Office of the People's Republic of China (PRC) for "a purified recombinant batroxobin with high bioactivity".
The patent application (#031160549) comprises a DNA recombinant technology to fabricate batroxobin, which exists naturally in the venom of the pallas pit viper. The invention also covers the synthesis of the batroxobin gene, as well as the expression, purification and characterization of batroxobin. Shanghai Wanxing applied for the Chinese patent for rBAT in 2003.
In addition, The Patent Cooperation Treaty (PCT) issued Sinobiomed's recombinant batroxobin international application number PCT/CN2007/001036 on March 30, 2007.
Natural batroxobin is the world's most prescribed biological anti-bleeding agent, but also has high production costs and safety concerns. In China, natural batroxobin currently has more than 80 percent of the domestic market.
rBAT is the world's first batroxobin synthesized through gene recombination. Shanghai Wanxing's low-cost, high-yield production process enhances bioactivity and guarantees the highest levels of purity. Shanghai Wanxing developed rBAT to prevent and treat surgical bleeding; it is now in Phase II Clinical Trials.
"The State Intellectual Property Office's granting of this patent for recombinant batroxobin confirms Sinobiomed's ability to identify unmet or underserved medical needs and develop innovative, patentable products to meet them," said Company President and CEO Banjun Yang.
The granting of the Chinese patent for recombinant batroxobin follows the granting of three other important patents for Sinobiomed's malaria vaccine. The U.S. Patent Office, the European Patent Office and most recently IP Australia, the Australian government organization that administers patents, has granted a patent for the malaria vaccine PfCP2.9 to which Sinobiomed has exclusive rights...
|
|
More articles from M2 Presswire
This Report Is An Essential Source For Key Data Relating To The Europe..., July 31, 2007
Clean Hydrogen Producers (Pink Sheets: CHPO) anounces its Listing on t..., July 31, 2007
Qwoter.com Reports On (OTCBB: SZSN), (Pinksheets:EXMT)., July 31, 2007
UpTick.com Pandemic Influenza Research Sector Alert -- Major Movements..., July 31, 2007
Stocks on the Rise UCMT, UDSG, and WTVI., July 31, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
